# Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
Canonical URL: https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-new-18-4-million-non-convertible-note-financing-and-amendment-to-existing-convertible-note
Ticker: OTLK
Company: Outlook
Source: Outlook
Published: 2026-03-16 12:05 EST
Original Source URL: https://ir.outlooktherapeutics.com
## Summary

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale

## Article Body
ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale
## Recent Company News
- 2026-06-01 12:46 EST — [Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-resubmission-of-biologics-license-application-to-u-s-fda-for-ons-5010-lytenavatm-bevacizumab-vikg) — Source: Outlook
- 2026-05-28 20:00 EST — [Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-pricing-of-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules) — Source: Outlook
- 2026-05-26 11:00 EST — [Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-wins-appeal-following-formal-dispute-resolution-process-for-ons-5010-lytenavatm-bevacizumab-vikg) — Source: Outlook
- 2026-05-15 20:05 EST — [Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update) — Source: Outlook
- 2026-04-23 20:05 EST — [Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-closing-of-5-0-million-registered-direct-offering) — Source: Outlook
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)